RxDoctor Payments Data

Willis Holloway, MD

Psychiatry · Oklahoma City, OKNPI 1023054434

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $80,718 of the $91,590 with a category attached, or 88.1%. Otsuka America Pharmaceutical, Inc. accounts for 61.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $40,831 and has fallen 98.2% since, to $730 in 2025. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$91,590in general payments, 2019–2025

Across 304 payments — averaging $301.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$56K
  • Supernus Pharmaceuticals, Inc.$25K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
  • Johnson & Johnson$4K
  • Boehringer Ingelheim$1K
  • Vanda Pharmaceuticals Inc.$255
  • plus $1K from 16 others
$1,301,624in research payments, 2019–2025

Across 224 payments — averaging $5810.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$332K
  • Genentech, Inc.$234K
  • AbbVie$164K
  • F. Hoffmann-la Roche AG$160K
  • Janssen Research & Development, LLC$152K
  • Sunovion Pharmaceuticals Inc.$62K
  • plus $197K from 10 others

What the payments were for

  • Consulting fees$7201%
  • Speaking & faculty fees$80,71888%
  • Travel & lodging$5,7256%
  • Food & beverage$4,4285%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,590 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$5,747
Medicare patients
81
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvanseLisdexamfetamine Dimesylate56$21,420
Lisdexamfetamine Dimesylate55$11,130
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine267$7,647
Clozapine122$7,579
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl55$4,509
Naltrexone Hcl22$2,144
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine46$1,743
Methylphenidate Hcl38$1,414
Quetiapine Fumarate42$943
Clonazepam87$608
Carbamazepine ErCarbamazepine12$584
Lurasidone Hcl16$574
Lorazepam50$543
Hydroxyzine Pamoate24$444
Duloxetine Hcl12$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$40$21,42056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →